This unreleased app is quite accurate when it comes to detecting COVID-19
This application is called ‘ResApp’, and it uses machine learning to analyze your cough. What’s also interesting is that Pfizer offered to acquire ResApp for $0.115 per share, in Cash, which comes down to $74.3 million overall.
741 patients in the US and India tested this app, 446 of which were infected with COVID-19. The app correctly diagnosed 92% of them. People who were tested were required to fill out paperwork, sharing their symptoms, and then they coughed into a smartphone. In order to see whether the app can differentiate coughs, patients with asthma, pneumonia, and respiratory tract infections also tested the app. 1,007 patients with non-COVID breathing issues also tested this app, and 90-percent of the time the correct diagnosis was made.
The app could be quite useful in sports, entertainment, healthcare, and more
The developers see this app as being really useful in sports, entertainment, healthcare, and travel. In areas where quick tests can be quite useful. With such a percentage of accuracy, it’s possible it could be useful. Professor Catherine Bennet, a member of ResApp’s COVID-19 Scientific Advisory Board, said the following: “By rapidly ruling out Covid-19, ResApp’s COVID-19 test would significantly reduce the number of rapid antigen and PCR tests required, while still maintaining the disease surveillance needed to manage the continued impact of COVID-19”. The company’s CEO and Managing Director, Tony Keating, said that the company intends to accelerate commercialization. It will engage regulators globally, and do its best to push the product to the market. It was also highlighted that this app is better for the environment than PCR tests. That is obvious, if you think about it for a second. The fact that Pfizer actually wanted to buy the app does say a lot. Needless to say, having a smartphone app that can accurately test for COVID could be quite useful.
